Andere Sprachen MIRA Pharmaceuticals, Inc.

Aktien

A3EQWL

US60458C1045

MIRA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 14.06.2024			% 5 Tage	% 1. Jan.
0,738 ^USD	+3,93 %		-2,89 %	-29,71 %

10.06.	MIRA Pharmaceuticals, Inc. gibt positive präklinische Studienergebnisse für sein neuartiges orales Ketamin-Analogon Ketamir-2 bekannt und ebnet damit den Weg für einen IND-Antrag im Laufe dieses Jahres	CI
29.05.	Sektor-Update: Aktien des Gesundheitswesens fallen am spaten Nachmittag	MT

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year	10.06.
MIRA Pharmaceuticals, Inc. Announces Positive Preclinical Study Results for Its Novel Oral Ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year	10.06.
Sector Update: Health Care Stocks Fall Late Afternoon	29.05.
Sector Update: Health Care Stocks Retreat Wednesday Afternoon	29.05.
Mira Pharmaceuticals Says US DEA Finds Marijuana Analog a Non-Controlled Substance	29.05.
Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance	29.05.
MIRA Pharmaceuticals, Inc. Announces DEA Rules Mira-55, A Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as A Controlled Substance	29.05.
MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog	21.05.
Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog	20.05.
Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, A Differentiated Oral Ketamine Analog	20.05.
MIRA Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13.05.
Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission	02.04.
Mira Pharmaceuticals, Inc. Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission	02.04.
MIRA Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01.04.
MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor	21.03.
Mira Pharmaceuticals Inc. Announces Appointment of Itzchak Angel as Chief Scientific Advisor	21.03.
MIRA Pharmaceuticals, Inc. Announces Management Changes	13.03.
MIRA Pharmaceuticals, Inc. Provides Updated Information Regarding the Patented, Pre-Clinical Drug Candidate Molecule Known as Mira1a	07.03.
MIRA Pharmaceuticals Provides Corporate Update	05.02.
Certain Stock Options of MIRA Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-JAN-2024.	30.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen MIRA Pharmaceuticals, Inc.

Aktien

A3EQWL

US60458C1045

MIRA

Andere Sprachen

Filter